A study which was funded by Cell Pathways Inc., developer of the drug Exisulind, suggest that Exisulind may delay disease progression in men with recurrent prostate cancer according to Dr. Erik Goluboff, Assistant Professor of Urology at Columbia University College of Physicians & Surgeons, Director of Urology at The Allen Pavilion of New York-Presbyterian Hospital, [...]
At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]
I have to admit that cancer researchers are becoming very creative. There is a phase II clinical trial getting ready to start at the Wake Forest University Baptist Medical Center which has a new twist. The treatment is based on injecting white blood cells called 'cancer killing' granulocytes from healthy donors into cancer survivors with [...]
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) has announced a new phase I/II clinical trial of Apoptone (HE3235) for late stage prostate cancer. Howard Scher, M.D., Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center said "The preclinical data generated to date suggest that Apoptone may offer a unique therapeutic approach to late-stage prostate cancer where [...]
Posted on the Prostate Problems Mailing list about two months ago was a notice from Dr. Richard Lam about a clinical trial in which his office, Prostate Oncology Specialists, will participate. What I found particularly interesting in this trial is that it was evaluating a potential new drug, abiraterone acetate, which could be used after [...]